COLD SORE TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In February 2024, Abreva promoted confidence among cold sore sufferers by introducing a distinctive, diamond-studded lip design. This striking piece is intended to challenge the stigma surrounding cold sores and encourage individuals to embrace their condition openly. Studies reveal that two-thirds of young people with cold sores experience diminished self-esteem and confidence when have an outbreak.
• In December 2022, BioNTech initiated a Phase 1 clinical trial for BNT163, an mRNA vaccine aimed at preventing genital lesions caused by HSV-2 and potentially HSV-1. The trial will assess the vaccine's safety, tolerability, and effectiveness in inducing an immune response. BNT163 targets three HSV-2 glycoproteins to block HSV entry and spread and counteract its immunosuppressive effects.
• In July 2021, Devirex announced the launch of Lipivir. The company entered a new phase of development, transitioning from lab creation to market distribution. Lipivir lip gel, designed to prevent cold sores, was initially available in pharmacies, drugstores, beauty spas, and online in Switzerland and Austria at the beginning of 2021, following extensive development, research, and testing.
• In November 2020, Amneal Pharmaceuticals, Inc. announced that the FDA had approved its Abbreviated New Drug Application (ANDA) for Acyclovir Cream, 5%. This generic version of Zovirax is used to treat recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents aged 12 and older. The cream is available by prescription only and may cause mild side effects like nausea.